Close Menu

NEW YORK (GenomeWeb) – Although researchers at Memorial Sloan Kettering Cancer Center have been early adopters of several commercial liquid biopsy assays in the last few years, the institute is now close to launching its own assay, reflecting a strategy it first pursued in tissue genomics with the MSK-IMPACT test.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.